Aegerion to submit lomitapide in Japan near year end; SciClone Theravance deal on Vibativ in China;

> Aegerion Pharmaceuticals ($AEGR) said it will submit an NDA for lomitapide in Japan in the fourth quarter of this year or early 2016 based on Phase III trial results meeting their primary endpoint. Release

> China-focused SciClone Pharmaceuticals and Theravance Biopharma entered into an agreement granting SciClone exclusive development and commercial rights for the antibiotic Vibativ in China and certain adjacent territories. Release